We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Biodexa Pharmaceuticals Plc (BDRX) ADR Each Representing 400 Ord Shares SPON

Sell:$0.28 Buy:$0.29 Change: $0.0034 (1.17%)
Market closed |  Prices as at close on 26 September 2024 | Switch to live prices |
Sell:$0.28
Buy:$0.29
Change: $0.0034 (1.17%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 September 2024 | Switch to live prices |
Sell:$0.28
Buy:$0.29
Change: $0.0034 (1.17%)
Market closed |  Prices as at close on 26 September 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Contact details

Address:
1 Caspian Point, Caspian Way
ABINGDON
CF10 4DQ
United Kingdom
Telephone:
+44 (1235) 841575
Website:
https://www.biodexapharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BDRX
ISIN:
US59564R7089
Market cap:
$4.23 million
Shares in issue:
1.19 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Stephen Stamp
    Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
  • Dmitry Zamoryakhin
    Chief Scientific Officer
  • Vincent Holmes
    Vice President - Head of Clinical Operations
  • Daniel Palmer
    Vice President - Technology
  • Steve Ellul
    Vice President - Business Development
  • Fiona Sharp
    Group Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.